<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">21618414</PMID>
<DateCompleted>
<Year>2012</Year>
<Month>05</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised>
<Year>2016</Year>
<Month>11</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1545-5017</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>58</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2012</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Pediatric blood &amp; cancer</Title>
<ISOAbbreviation>Pediatr Blood Cancer</ISOAbbreviation>
</Journal>
<ArticleTitle>Ofatumumab for a rituximab-allergic child with chronic-relapsing paraneoplastic opsoclonus-myoclonus.</ArticleTitle>
<Pagination>
<MedlinePgn>988-91</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/pbc.23187</ELocationID>
<Abstract>
<AbstractText>Ofatumumab is a fully human anti-CD20 monoclonal antibody in phase II-III trials for various autoimmune and lymphoreticular diseases. We used it to treat a rituximab-allergic child with severe, chronic-relapsing, opsoclonus-myoclonus syndrome (OMS), characterized by persistent cerebrospinal fluid (CSF) B-cell expansion and T-cell dysregulation. He had relapsed despite chemotherapy, plasma exchange with immunoadsorption, and resection of ganglioneuroblastoma, detected 3 years after OMS onset. The four ofatumumab infusions (1,195 mg/m(2) total dose) were well tolerated, and CSF B-cell expansion was eliminated. No further relapses have occurred in 3 years, but he remains on low-dose ACTH with neuropsychiatric residuals of OMS.</AbstractText>
<CopyrightInformation>Copyright © 2011 Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pranzatelli</LastName>
<ForeName>Michael R</ForeName>
<Initials>MR</Initials>
<AffiliationInfo>
<Affiliation>Southern Illinois University School of Medicine, Springfield, IL, USA. mpranzatelli@siumed.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Tate</LastName>
<ForeName>Elizabeth D</ForeName>
<Initials>ED</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shenoy</LastName>
<ForeName>Shalini</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Travelstead</LastName>
<ForeName>Anna L</ForeName>
<Initials>AL</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2011</Year>
<Month>05</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Pediatr Blood Cancer</MedlineTA>
<NlmUniqueID>101186624</NlmUniqueID>
<ISSNLinking>1545-5009</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058846">Antibodies, Monoclonal, Murine-Derived</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>4F4X42SYQ6</RegistryNumber>
<NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>M95KG522R0</RegistryNumber>
<NameOfSubstance UI="C527517">ofatumumab</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000911">Antibodies, Monoclonal</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D058846">Antibodies, Monoclonal, Murine-Derived</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004342">Drug Hypersensitivity</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018305">Ganglioneuroblastoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053578">Opsoclonus-Myoclonus Syndrome</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000069283">Rituximab</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013120">Spinal Cord Neoplasms</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2011</Year>
<Month>03</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2011</Year>
<Month>04</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2011</Year>
<Month>5</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2011</Year>
<Month>5</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2012</Year>
<Month>5</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">21618414</ArticleId>
<ArticleId IdType="doi">10.1002/pbc.23187</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>